Caption Management’s Blueprint Medicines BPMC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-27,100
Closed -$3.47M 1687
2025
Q2
$3.47M Buy
+27,100
New +$2.81M 0.04% 522
2025
Q1
Sell
-11,700
Closed -$1.02M 1549
2024
Q4
$1.02M Sell
11,700
-89,100
-88% -$8.16M 0.01% 906
2024
Q3
$9.32M Buy
100,800
+72,200
+252% +$7.17M 0.15% 166
2024
Q2
$3.08M Buy
28,600
+3,600
+14% +$360K 0.05% 389
2024
Q1
$2.37M Sell
25,000
-14,000
-36% -$1.2M 0.04% 488
2023
Q4
$3.6M Buy
39,000
+14,000
+56% +$907K 0.05% 447
2023
Q3
$1.26M Buy
+25,000
New +$1.34M 0.02% 706
2022
Q3
Sell
-25,000
Closed -$1.26M 1508
2022
Q2
$1.26M Buy
+25,000
New +$1.46M 0.02% 795
2022
Q1
Sell
-25,000
Closed -$2.68M 1481
2021
Q4
$2.68M Buy
+25,000
New +$2.62M 0.03% 683
2019
Q4
Sell
-127,100
Closed -$9.34M 829
2019
Q3
$9.34M Buy
127,100
+35,800
+39% +$3.09M 0.49% 46
2019
Q2
$8.61M Buy
+91,300
New +$7.54M 0.43% 47

Other funds holding BPMC

Caption Management's BPMC Position: Q2 2025 in Review

Caption Management sold out of Blueprint Medicines (BPMC) in Q2 2025, closing a stake of 7,000 shares — an estimated $727K sold.

Caption Management first reported a position in BPMC in Q1 2019 and held it in 7 quarters. The position peaked at $3.67M in Q3 2019. 354 funds tracked by Wall St. Rank hold BPMC as of Q2 2025.

  • Caption Management reported no remaining Blueprint Medicines position as of Q2 2025 after selling out during the quarter.
  • Caption Management sold 7,000 Blueprint Medicines shares in Q2 2025, an estimated $727K.
  • Caption Management first reported a position in Blueprint Medicines in Q1 2019 and held it in 7 quarters.
  • Caption Management's Blueprint Medicines position peaked at $3.67M in Q3 2019.
  • 354 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2025.

Based on Caption Management's 13F filing for Q2 2025, filed 14 Aug 2025.